Skip to main content
SpringerLink
Log in

Alterations of the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase-inhibitor valproic acid and interferon-alpha

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

Renal cell carcinoma (RCC) is highly resistant to chemotherapy and unresponsive to radio- and immunotherapy. Recently, we have documented that the histone deacetylase (HDAC)-inhibitor valproic acid (VPA) in combination with low-dosed interferon (IFN)-alpha significantly inhibits RCC proliferation and adhesion in vitro and in vivo. The current study investigated the effects of these compounds on gene transcription of metastatic RCC cell line Caki-1 after 3 and 5 days exposure.

Methods

To evaluate the gene expression profiles of the RCC cells, we performed microarray analysis using Affymetrix GeneChip. Selected significant genes were further validated by Real Time PCR.

Results

Microarray revealed that VPA altered genes that are involved in cell growth, cell survival, immune response, cell motility and cell adhesion. Combination of VPA with IFN-alpha not only enhanced the effects on gene transcription but also resulted in the expression of novel genes, which were not induced by either VPA or IFN-alpha alone. Among the up-regulated genes were chemokines (CXCL10, CXCL11, CXCL16) and integrins (ITGA2, ITGA4, ITGA5, ITGA6, ITGA7). Genes encoding for adhesion molecules (NCAM1, ICAM1, VCAM1) were also modulated. Real Time PCR approved these findings.

Conclusion

This data provides insight into the molecular mechanism of action of the combined treatment of VPA and IFN-alpha in RCC. Implications are that the combined application of VPA and IFN-alpha may represent a more efficient alternative to existing therapy options for RCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34:206–222

    Article  PubMed  CAS  Google Scholar 

  2. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769–784

    Article  PubMed  CAS  Google Scholar 

  3. Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D, Blaheta RA (2009) The Histone Deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med 13(8B):2376–2385

    Article  PubMed  Google Scholar 

  4. Wedel SA, Mickuckyte A, Juengel E, Jones J, Hudak L, Jonas D, Blaheta RA (2008) Preclinical studies on the influence of the tyrosine kinase inhibitor AEE788 on malignant properties of renal cell carcinoma cells. Urologe 47(9):1175–1181

    Article  PubMed  CAS  Google Scholar 

  5. Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D, Hintereder G, Blaheta RA (2009) Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix. J Cell Mol Med 13(8B):2342–2352

    Article  PubMed  Google Scholar 

  6. Negrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R, Sevin E, Caty A, Escudier B, For The French Immunotherapy Intergroup (2007) Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110(11):2468–2477

    Article  PubMed  CAS  Google Scholar 

  7. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20(1):289–296

    Article  PubMed  CAS  Google Scholar 

  8. Certa U, Wilhelm-Seiler M, Foser S, Broger C, Neeb M (2003) Expression modes of interferon-α inducible genes in sensitive and resistant human melanoma cells stimulated with regular and pegylated interferon-α. Gene 315:79–86

    Article  PubMed  CAS  Google Scholar 

  9. Blaheta RA, Michaelis M, Natsheh I, Hasenberg C, Weich E, Relja B, Jonas D, Doerr HW, Cinatl J Jr (2007) Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium. Br J Canc 96:1699–1706

    Article  CAS  Google Scholar 

  10. Xia Q, Sung J, Chowdhury W, Chen CL, Hoti N, Shabbeer S, Carducci M, Rodriguez R (2006) Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Canc Res 66:7237–7244

    Article  CAS  Google Scholar 

  11. Kaur S, Sassano A, Joseph AM, Majchrzak-Kita B, Eklund EA, Verma A, Brachmann SM, Fish EN, Platanias LC (2008) Dual regulatory role of phohpatidylinositol 3-kinase in IFN signaling. J Immunol 181(10):7316–7323

    PubMed  CAS  Google Scholar 

  12. Miles A, Liaskou E, Eksteen B, Lalor PF, Adams DH (2008) CCL25 and CCL28 promote alpha4 beta7-integrin-dependent adhesion of lymphocytes to MAdCAM-1 under shear flow. Am J Physiol Gastrointest Liver Physiol 294(5):G1257–G1267

    Article  PubMed  CAS  Google Scholar 

  13. Naschberger E, Croner RS, Merkel S, Dimmler A, Tripal P, Amann KU, Kremmer E, Brueckl WM, Papadopoulos T, Hohenadl C, Hohenberger W, Stürzl M (2008) Angiostatic immune reaction in colorectal carcinoma: impact on survival and perspectives for antiangiogenic therapy. Int J Cancer 123:2120–2129

    Article  PubMed  CAS  Google Scholar 

  14. Xu QY, Gao Y, Liu Y, Yang WZ, Xu XY (2008) Identification of differential gene expression profiles of radioresistant lung cancer cell lines established by fractionated ionizing radiation in vitro. Chin Med J 121(18):1830–1837

    PubMed  CAS  Google Scholar 

  15. Reckamp KL, Figlin RA, Moldawer N, Pantuck AJ, Belldegrun AS, Burdick MD, Strieter RM (2007) Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy. J Immunother 30(4):417–424

    Article  PubMed  CAS  Google Scholar 

  16. Viey E, Lucas C, Romagne F, Escudier B, Chouaib S, Caignard A (2008) Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients. J Immunother 31(3):313–323

    Article  PubMed  CAS  Google Scholar 

  17. Tanabe K, Campbell SC, Alexander JP, Steinbach F, Edinger MG, Tubbs RR, Novick AC, Klein EA (1997) Molecular regulation of intercellular adhesion molecule 1 (ICAM-1) expression in renal cell carcinoma. Urol Res 25(4):231–238

    Article  PubMed  CAS  Google Scholar 

  18. Perut F, Cenni E, Unger RE, Kirkpatrick CJ, Giunti A, Baldini N (2009) Immunogenic properties of renal cell carcinoma and the pathogenesis of osteolytic bone metastases. Int J Oncol 34(5):1387–1393

    PubMed  CAS  Google Scholar 

  19. Wu XX, Zeng Y, Jin XH, Kakehi Y (2007) Enhanced susceptibility of adriamycin-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes and tumor infiltrating lymphocytes. Oncol Rep 18(2):353–359

    PubMed  CAS  Google Scholar 

  20. Gati A, Da Rocha S, Guerra N, Escudier B, Moretta A, Chouaib S, Angevin E, Caignard A (2004) Analysis of the natural killer mediated immune response in metastatic renal cell carcinoma patients. Int J Cancer 109(3):393–401

    Article  PubMed  CAS  Google Scholar 

  21. Jee CD, Kim MA, Jung EJ, Kim J, Kim WH (2009) Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma. Eur J Cancer [Epub ahead of print]

  22. Feng Q, Sekula D, Guo Y, Liu X, Black CC, Galimberti F, Shah SJ, Sempere LF, Memoli V, Andersen JB, Hassel BA, Dragnev K, Dmitrovsky E (2008) UBE1L causes lung cancer growth suppression by targeting cyclin D1. Mol Cancer Ther 7(12):3780–3788

    Article  PubMed  CAS  Google Scholar 

  23. Li Q, Tang L, Roberts PC, Kraniak JM, Fridman AL, Kulaeva OI, Tehrani OS, Tainsky MA (2008) Interferon regulatory factors IRF5 and IRF7 inhibit growth and induces senescence in immortal Li-Fraumeni fibroblasts. Mol Cancer Res 6(5):770–784

    Article  PubMed  CAS  Google Scholar 

  24. Moschos SJ, Drogowski LM, Reppert SL, Kirkwood JM (2007) Integrins and cancer. Oncology (Williston Park) 21(9):13–20

    Google Scholar 

  25. Guo W, Giancotti FG (2004) Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5:816–826

    Article  PubMed  CAS  Google Scholar 

  26. Oertl A, Relja B, Makarevic J, Weich E, Höfler S, Jones J, Jonas D, Bratzke H, Baer PC, Blaheta RA (2006) Altered expression of beta1 integrins in renal carcinoma cell lines exposed to the differentiation inducer valproic acid. Int J Mol Med 18:347–354

    PubMed  CAS  Google Scholar 

  27. Markovic-Lipkovski J, Brasanac D, Muller GA, Muller CA (2001) Cadherins and integrins in renal cell carcinoma: an immunohistochemical study. Tumori 87:173–178

    PubMed  CAS  Google Scholar 

  28. Jones J, Berkhoff S, Weich E, Engl T, Wedel S, Relja B, Jonas D, Blaheta RA (2007) Transient down-regulation of beta1 integrin subtypes on kidney carcinoma cells is induced by mechanical contact with endothelial cell membranes. J Cell Mol Med 11:826–838

    Article  PubMed  CAS  Google Scholar 

  29. Welser JV, Lange ND, Flintoff-Dye N, Burkin HR, Burkin DJ (2007) Placental defects in alpha7 integrin null mice. Placenta 28:1219–1228

    Article  PubMed  CAS  Google Scholar 

  30. Welser JV, Lange N, Singer CA, Elorza M, Scowen P, Keef KD, Gerthoffer WT, Burkin DJ (2007) Loss of the α7 integrin promotes extracellular signal-regulated kinase activation and altered vascular remodeling. Circ Res 101(7):672–681

    Article  PubMed  CAS  Google Scholar 

  31. Ren B, Yu YP, Tseng GC, Wu C, Chen K, Rao UN, Nelson J, Michalopoulos GK, Luo JH (2007) Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma. J Natl Cancer Inst 99(11):868–880

    Article  PubMed  CAS  Google Scholar 

  32. Lin KY, Lu D, Hung CF, Peng S, Huang L, Jie C, Murillo F, Rowley J, Tsai YC, He L, Kim DJ, Jaffee E, Pardoll D, Wu TC (2007) Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res 67:1832–1841

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We would like to thank Elsie Oppermann and Karen Nelson critically reading the manuscript and Marie Joseph for introduction to the microarrays. This study was supported by grants of the Boehringer Ingelheim Fonds, Horst Müggenburg Stiftung and the Freunde und Förderer der Goethe-Universität.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Klinik für Urologie und Kinderurologie, Zentrum der Chirurgie, Klinikum der Johann Wolfgang Goethe-Universität, Interdisziplinäres Forschungs- und Laborgebäude, Chirurgische Forschung, Haus 25, Zi 212, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany

    E. Juengel, J. Jones, L. Hudak, D. Jonas & R. A. Blaheta

  2. Genomics Center, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, Boston, MA, USA

    M. Bhasin & T. Libermann

  3. blue-drugs GmbH, Frankfurt, Germany

    S. Barth & M. Michaelis

  4. Institut für Medizinische Virologie, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt, Germany

    M. Michaelis & J. Cinatl Jr

Authors
  1. E. Juengel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Bhasin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Libermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Barth
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Michaelis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Cinatl Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L. Hudak
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D. Jonas
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R. A. Blaheta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Juengel.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Juengel, E., Bhasin, M., Libermann, T. et al. Alterations of the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase-inhibitor valproic acid and interferon-alpha. World J Urol 29, 779–786 (2011). https://doi.org/10.1007/s00345-010-0582-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-010-0582-y

Keywords

Search

Navigation